These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891 [TBL] [Abstract][Full Text] [Related]
4. Detection and localisation of primary prostate cancer using Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602 [TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of clinically significant prostate cancer detection with [ Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727 [TBL] [Abstract][Full Text] [Related]
6. A comparison study of 68gallium-prostate-specific membrane antigen positron emission tomography-computed tomography and multiparametric magnetic resonance imaging for locoregional staging of prostate cancer. Patel KS; Singh T; Raghuvanshi K; Sonar S; Chaudhari R Urol Sci; 2024 Mar; 35(1):36-41. PubMed ID: 38566885 [TBL] [Abstract][Full Text] [Related]
7. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
8. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093 [TBL] [Abstract][Full Text] [Related]
13. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748 [TBL] [Abstract][Full Text] [Related]
14. Status of Tang Y; Ji X; Lin Q; Huang H; Zhu H; Huang X; Xie H; Chen W; Zhuang Y World J Urol; 2023 Apr; 41(4):1017-1024. PubMed ID: 36932282 [TBL] [Abstract][Full Text] [Related]
15. Detection of prostate cancer with Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250 [TBL] [Abstract][Full Text] [Related]
16. Multiparametric MRI and Privé BM; Israël B; Janssen MJR; van der Leest MMG; de Rooij M; van Ipenburg JA; Jonker M; Peters SMB; de Groot M; Zámecnik P; Hoepping A; Bomers JG; Gotthardt M; Sedelaar JPM; Barentsz JO; van Oort IM; Nagarajah J Radiology; 2024 May; 311(2):e231879. PubMed ID: 38771185 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer. Deka H; Pooleri GK; Suguna B; Rajeshkannan R; Sekhar R; Bindhu MR; Prasad V World J Urol; 2024 Mar; 42(1):153. PubMed ID: 38483621 [TBL] [Abstract][Full Text] [Related]
18. Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial. Bahler CD; Tachibana I; Tann M; Collins K; Swensson JK; Green MA; Mathias CJ; Tong Y; Yong C; Boris RS; Brocken E; Hutchins GD; Sims JB; Hill DV; Smith N; Ferari C; Love H; Koch MO J Urol; 2024 Aug; 212(2):290-298. PubMed ID: 38785259 [TBL] [Abstract][Full Text] [Related]
19. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189 [TBL] [Abstract][Full Text] [Related]